June 28, 2024 04:31 PM EDT

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

Max Bayer

Pharma Reporter

Pierre Fabre’s overactive bladder medication won approval in Europe on Friday as a panel of experts at the European Medicines Agency separately recommended 10 others …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

EMA's CHMP rec­om­mends 10 new drugs as Pierre Fab­re over­ac­tive blad­der med wins ap­proval

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B